Targets › COL18A1
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Feb 2027.
Probably plays a major role in determining the retinal structure as well as in the closure of the neural tube..; FUNCTION: [Non-collagenous domain 1]: May regulate extracellular matrix-dependent motility and morphogenesis of endothelial and non-endothelial cells; the function requires homotrimerization and implicates MAPK signaling..; FUNCTION: [Endostatin]: Potently inhibits endothelial cell proliferation and…. (UniProt, P39060)
Open in Phaseline: the race on COL18A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chongqing University Cancer Hospital | Recombinant human endostatin Endostatin - angiogenesis inhibitor derived from collagen XVIII | COL18A1 | Phase 2 | Nasopharyngeal Carcinoma | Feb 2027 |
| Hua Zhang | Recombinant Human Endostatin Injection (Endostar) Endogenous angiogenesis inhibitor; anti-angiogenic agent | COL18A1 | Phase 2 | Unresectable Non-small Cell Lung Cancer | Sep 2027 |
Unresectable Non-small Cell Lung Cancer (1) Nasopharyngeal Carcinoma (1)
antibody (2)
Hua Zhang (1) Chongqing University Cancer Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.